Business Context and Reporting Period
This Form 8-K is a current report filed by India Globalization Capital, Inc. (noted as IGC Pharma, Inc. in metadata) on March 23, 2016. The filing discloses an unregistered sale of equity securities pursuant to Item 3.02.
Key Financial Metrics
- Capital Raised: $300,000 total purchase price.
- Shares Issued: 681,818 shares of common stock.
- Implied Price Per Share: Approximately $0.44.
- Post-Transaction Outstanding Shares: Approximately 23,289,220 shares.
- Revenue, Profit, Cash Flow, Debt, Liquidity: The filing text does not provide a clear value for these operational or balance sheet metrics.
Material Changes
The company entered into a Q4 2016 Stock Purchase Agreement with certain investors. The transaction closed on March 23, 2016, subject to customary conditions including NYSE approval. The shares issued are restricted common shares. The transaction was not registered under the Securities Act of 1933, relying instead on the exemption provided by Section 4(a)(2).
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the anticipated closing of the offering. Management notes that risks and uncertainties are detailed in the company's periodic filings, including Form 10-K and Form 10-Q. A press release announcing the closing was issued on March 29, 2016.
Investor Verification Checklist
- Verify the final approval status of the offering by the NYSE.
- Confirm the exact number of shares outstanding post-closing in subsequent filings.
- Review the full text of the Q4 2016 Stock Purchase Agreement (Exhibit 10.1) for specific investor rights or covenants.
- Check the March 29, 2016 press release (Exhibit 99.1) for additional context on the use of proceeds.